Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul C Brown

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Toxicologic Pathology|January 30, 2015
Regulatory Forum Opinion Piece*: Transgenic/Alternative Carcinogenicity Assays: A Retrospective Review of Studies Submitted to CDER/FDA 1997-2014Abigail C Jacobs, Paul C Brown
Regulatory Toxicology and Pharmacology : RTP|July 15, 2023
Considerations regarding the use of nonhuman primates in assessing safety endpoints for pharmaceuticalsPaul C Brown, Ronald L Wange
Regulatory Toxicology and Pharmacology : RTP|May 13, 2021
Implementation of the principles of the 3Rs of animal testing at CDER: Past, present and futureRonald L Wange, Paul C Brown, Karen L Davis-Bruno
Toxicologic Pathology|October 8, 2021
Regulatory Perspectives on Juvenile Animal Toxicologic PathologyDeepa B Rao, Alan M Hoberman, Paul C Brown, et al.
Toxicologic Pathology|October 27, 2004
CDER photosafety guidance for industryAbigail C Jacobs, Paul C Brown, Conrad Chen, et al.
Regulatory Toxicology and Pharmacology : RTP|February 6, 2023
Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologiesAmy M Avila, Ilona Bebenek, Donna L Mendrick, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|June 14, 2023
Parallel evaluation of alternative skin barrier models and excised human skin for dermal absorption studies in vitroAlec T Salminen, Kelly J Davis, Robert P Felton, et al.
Toxicology Letters|October 3, 2025
Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platformQiang Shi, Laura K Schnackenberg, Lijun Ren, et al.
The AAPS Journal|March 21, 2013
CDER risk assessment exercise to evaluate potential risks from the use of nanomaterials in drug productsCelia N Cruz, Katherine M Tyner, Lydia Velazquez, et al.
Regulatory Toxicology and Pharmacology : RTP|April 24, 2020
An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs)Amy M Avila, Ilona Bebenek, Jessica A Bonzo, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Toxicologic Pathology|January 30, 2015
Regulatory Forum Opinion Piece*: Transgenic/Alternative Carcinogenicity Assays: A Retrospective Review of Studies Submitted to CDER/FDA 1997-2014Abigail C Jacobs, Paul C Brown
Regulatory Toxicology and Pharmacology : RTP|July 15, 2023
Considerations regarding the use of nonhuman primates in assessing safety endpoints for pharmaceuticalsPaul C Brown, Ronald L Wange
Regulatory Toxicology and Pharmacology : RTP|May 13, 2021
Implementation of the principles of the 3Rs of animal testing at CDER: Past, present and futureRonald L Wange, Paul C Brown, Karen L Davis-Bruno
Toxicologic Pathology|October 8, 2021
Regulatory Perspectives on Juvenile Animal Toxicologic PathologyDeepa B Rao, Alan M Hoberman, Paul C Brown, et al.
Toxicologic Pathology|October 27, 2004
CDER photosafety guidance for industryAbigail C Jacobs, Paul C Brown, Conrad Chen, et al.
Regulatory Toxicology and Pharmacology : RTP|February 6, 2023
Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologiesAmy M Avila, Ilona Bebenek, Donna L Mendrick, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|June 14, 2023
Parallel evaluation of alternative skin barrier models and excised human skin for dermal absorption studies in vitroAlec T Salminen, Kelly J Davis, Robert P Felton, et al.
Toxicology Letters|October 3, 2025
Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platformQiang Shi, Laura K Schnackenberg, Lijun Ren, et al.
The AAPS Journal|March 21, 2013
CDER risk assessment exercise to evaluate potential risks from the use of nanomaterials in drug productsCelia N Cruz, Katherine M Tyner, Lydia Velazquez, et al.
Regulatory Toxicology and Pharmacology : RTP|April 24, 2020
An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs)Amy M Avila, Ilona Bebenek, Jessica A Bonzo, et al.
Pageof 2